Disclosures for "The Effects of Lecanemab Treatment on Soluble CSF Aβ Protofibrils (PF) in Clarity AD"
-
Dr. Horie has received personal compensation for serving as an employee of Eisai Inc.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Mr. Shuta has received personal compensation for serving as an employee of Eisai Co., Ltd..
-
Mr. Tahara has nothing to disclose.
-
Mr. Kanekiyo has received personal compensation for serving as an employee of Eisai Inc. Mr. Kanekiyo has stock in Eisai Co Ltd..
-
Shobha Dhadda has received personal compensation for serving as an employee of Eisai Inc.
-
Larisa Reyderman has nothing to disclose.
-
Dr. Hersch has received personal compensation for serving as an employee of Eisai Inc.. Dr. Hersch has stock in Voyager Therapeutics. The institution of an immediate family member of Dr. Hersch has received research support from NIH. Dr. Hersch has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Irizarry has received personal compensation for serving as an employee of Eisai, Inc..
-
Dr. Kramer has received personal compensation for serving as an employee of Eisai Inc. Dr. Kramer has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Eisai Co., Ltd..